原料辞典検索/cetrimonium-chloride/CETRIMONIUM CHLORIDE
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

CETRIMONIUM CHLORIDE

標準 INCI 準拠: CETRIMONIUM CHLORIDE
抗菌剤帯電防止剤防腐剤乳化剤
[EU CosIng Official Definition] Cetrimonium Chloride is a quaternary ammonium salt that conforms generally to the formula:
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における CETRIMONIUM CHLORIDE のグローバル配合基準と処方特性とは?

CETRIMONIUM CHLORIDE(CAS番号: 112-02-7)は、化粧品処方において主に抗菌剤, 帯電防止剤, 防腐剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(配合制限)、欧州CosIng(配合制限)など6大法域の法定基準下で管理され、通常 1.3–8.33%(適正安定域 pH 4–8)で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for CETRIMONIUM CHLORIDE
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)CETRIMONIUM CHLORIDE (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)——
③ 欧州連合 (EU CosIng EC 1223/2009)CETRIMONIUM CHLORIDE
④ 米国一般化粧品 (US PCPC / MoCRA INCI)CETRIMONIUM CHLORIDE
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)西曲氯铵
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)CETRIMONIUM CHLORIDE (標準INCI参照 · 任意カタカナ音訳排除)

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for CETRIMONIUM CHLORIDE
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)配合制限GMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)配合制限GMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #6886
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for CETRIMONIUM CHLORIDE
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
米国 CIR 市販製品最大報告濃度hair_dye0.3~0.3%安全判定 (MoS≥100)115_draft_trimon.pdf ()
米国 CIR 市販製品最大報告濃度leave_on0.1~0.1%安全判定 (MoS≥100)115_draft_trimon.pdf ()
米国 CIR 市販製品最大報告濃度rinse_off0.08~3%安全判定 (MoS≥100)115_draft_trimon.pdf ()
欧州 SCCS 安全性評価上限 (MoS≥100)rinse_off≤ 2.5%安全判定 (MoS≥100) ()
欧州 SCCS 安全性評価上限 (MoS≥100)leave_on≤ 1%安全判定 (MoS≥100) ()
欧州 SCCS 安全性評価上限 (MoS≥100)face_cream≤ 0.5%安全判定 (MoS≥100) ()
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Rinse-off Cleansern=7
Min 1.3% · Q1 1.65% · Median 3% · Q3 4.985% · Max 8.33%
Rinse-off Cleanser — Rinse-off cleanser & surfactant system modifier
Verified Source: Global Starter Formulation Library Statistical Distribution (n=7, EVONIK 5 · GRANT 1 · SEPPIC 1) (cir_safety) · EVONIK 5 · GRANT 1 · SEPPIC 1
Typical Median: 3%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for CETRIMONIUM CHLORIDE
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 C — 洗い流し用クレンザー・シャンプー1.3% · 1.65% · 3% · 4.985% · 8.33%Rinse-off cleanser & surfactant system modifierGlobal Starter Formulation Library Statistical Distribution (n=7, EVONIK 5 · GRANT 1 · SEPPIC 1)
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Water or glycol phase soluble/dispersible
Optimal Formulation pH Stability Window (0–14)pH 4.0 – 8.0
0245.5791114

Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ GLYCERIN+ CAPRYLIC/CAPRIC TR…+ TOCOPHEROL✕ Verify phase compati…CETRIMONIUM CHLORIDE
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

代表商品名参考 (商標法第90条第1項第2号 記述的表示)
CETRIMONIUM CHLORIDE

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: CETRIMONIUM CHLORIDE | CAS No.: 112-02-7 | EC No.: 203-928-6 - Origin: SYNTHETIC | Functions: , , , - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [CETRIMONIUM CHLORIDE] · EU [CETRIMONIUM CHLORIDE] · CN [西曲氯铵] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Cetrimonium Chloride is a quaternary ammonium salt that conforms generally to the formula: Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , , , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: RESTRICTED | EU: RESTRICTED | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 6886 (西曲氯铵)) - [EU / COMPOSITION / limited] (Max 0.1%): - [EU / COMPOSITION / limited] (Max 2.5%): - [KR / COMPOSITION / limited] (Max 2.5%): - Official Safety & Historical Use Concentration (Layer 2): cir (reported_use, hair_dye): 0.3~0.3% / cir (reported_use, leave_on): 0.1~0.1% / cir (reported_use, rinse_off): 0.08~3% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [cleanser_rinse] Typical range: 1.3 ~ 8.33% (Median 3.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=7, EVONIK 5 · GRANT 1 · SEPPIC 1)) — Rinse-off cleanser & surfactant system modifier ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: CETRIMONIUM CHLORIDE ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 37409071 (2023, Clin Cosmet Investig Dermatol): Quaternary Ammonium Compounds and Contact Dermatitis: A Review and Considerations During the COVID-19 Pandemic - PMID 19889043 (2010, Int J Cosmet Sci): Simple and rapid analytical method for the simultaneous determination of cetrimonium chloride and alkyl alcohols in hair - PMID 38320244 (2024, Dermatitis): Allergic or Not: Final Interpretation of Doubtful Patch Test Reactions From the North American Contact Dermatitis Group,

関連査読付き学術論文 (NIH PubMed) (7)

Quaternary Ammonium Compounds and Contact Dermatitis: A Review and Considerations During the COVID-19 Pandemic [PMID: 37409071 · 2023]
Okeke CAV, Khanna R, Ehrlich A · Clin Cosmet Investig Dermatol (2023)

The recent global pandemic has resulted in increased use of quaternary ammonium compounds (QACs). Currently, QACs are active ingredients in 292 disinfectants recommended by the US EPA for use against SARS-CoV-2. Among QACs, benzalkonium chloride (BAK), cetrimonium bromide (CTAB), cetrimonium chloride (CTAC), didecyldimethylammonium chloride (DDAC), cetrimide, quaternium-15, cetylpyridinium chloride (CPC), and benzethonium chloride (BEC) were all identified as potential culprits of skin sensitivity. Given their widespread utilization, additional research is needed to better classify their dermal effects and identify other cross-reactors. In this review, we aimed to expand our knowledge about these QACs to further dissect its potential allergic and irritant dermal effects on healthcare workers during COVID-19.

Simple and rapid analytical method for the simultaneous determination of cetrimonium chloride and alkyl alcohols in hair conditioners [PMID: 19889043 · 2010]
Terol A, G&#xf3;mez-Mingot M, Maestre SE, Prats S, Luis Todol&#xed; J, Paredes E · Int J Cosmet Sci (2010)

A simple method for the simultaneous determination of a cationic surfactant (cetrimonium chloride) and four non-ionic surfactants (1-tetradecanol, 1-hexadecanol, 1-octadecanol and 1-eicosanol) has been developed. Direct extraction of the analytes from the sample with methanol and a subsequent separation using reversed-phase high-performance liquid chromatography with refractive index detection are the steps followed in the procedure. The column used was a Luna C18 and the mobile phase consisted of a 0.1 M KClO(4) solution prepared on a 95:5 mixture of methanol and water. This solution was adjusted to pH 2.8 with phosphoric acid. Recoveries close to 100% were obtained in spiked commercial hair conditioner samples for the surfactants assayed using this method. Limits of detection were 10.4, 16.7 and 22.9 mg kg(-1) of cetrimonium chloride, 1-hexadecanol, 1-hexadecanol and 1-1-octadecanol respectively. The methodology was successfully applied to nine commercial hair conditioners of several types and different brands. All hair conditioners but one contained at least two of the surfactants included in this study.

Allergic or Not: Final Interpretation of Doubtful Patch Test Reactions From the North American Contact Dermatitis Group, 2019-2020 [PMID: 38320244 · 2024]
Reeder MJ, Nihal A, Aravamuthan SR, Warshaw EM, DeKoven JG, Atwater AR, Houle MC, Adler BL, Silverberg JI, Taylor JS, Pratt MD, Belsito DV, Yu J, Botto NB, Mowad CM, Dunnick CA, DeLeo VA · Dermatitis (2024)

Background: Doubtful patch test reactions generally do not meet criterion for positivity in patch testing. However, the North American Contact Dermatitis Group (NACDG) allows for doubtful reactions to be coded with a final determination of "allergic/positive" based on the temporal pattern, appearance, known characteristics of the allergen, and/or other supportive patch test reactions. Objectives: To analyze NACDG data from the 2019-2020 patch test cycle to identify patterns in the interpretation and relevance of doubtful reactions. Methods: The frequency and proportions of doubtful reactions were tabulated and analyzed for patterns. Statistical analyses were limited to allergens with &#x2265;30 doubtful reactions to ensure adequate sample size. Results: Of patch-tested patients, 31.9% (1315/4121) had &#x2265;1 doubtful reaction. Of 2538 total doubtful reactions, 46% (n&#x2009;=&#x2009;1167) had a final interpretation of "allergic/positive." The allergens with the highest proportion of doubtful reactions at the final visit were hydroperoxides of linalool 1% (4.5%), fragrance mix I 8.0% (3.9%), and cetrimonium chloride 0.5% (3.4%). Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) 0.02% ( P &#x2009;&lt;&#x2009;0.001), MI 0.2% ( P &#x2009;&lt;&#x2009;0.001), nickel sulfate hexahydrate 2.5% ( P &#x2009;=&#x2009;0.001), and neomycin sulfate 20.0% ( P &#x2009;=&#x2009;0.003) doubtful reactions were more likely to be interpreted as allergic than nonallergic. Methyldibromoglutaronitrile/phenoxyethanol 0.2% ( P &#x2009;&lt;&#x2009;0.001), oleamidopropyl dimethylamine 0.1% ( P &#x2009;&lt;&#x2009;0.001), formaldehyde 2.0% ( P &#x2009;&lt;&#x2009;0.001), cetrimonium chloride 0.5% ( P &#x2009;&lt;&#x2009;0.001), benzophenone-4 (sulisobenzone) 10% ( P &#x2009;&lt;&#x2009;0.001), iodopropynyl butylcarbamate 0.5% ( P &#x2009;&lt;&#x2009;0.001), cocamidopropyl betaine 1.0% ( P &#x2009;=&#x2009;0.002), and benzisothiazolinone 0.1% ( P &#x2009;=&#x2009;0.012) doubtful reactions were less likely to be interpreted as allergic. Of the 1167 doubtful reactions interpreted as allergic, 84.9% had current relevance. Conclusions: Doubtful reactions were common and approximately one half were coded with a final interpretation of "allergic/positive." Of those, most were clinically relevant. MCI/MI, MI, nickel, and neomycin were more likely to be interpreted as allergic.

Allergic contact dermatitis secondary to the use of a bandage impregnated with benzalkonium chloride [PMID: 30094863 · 2018]
Zhang AJ, Boyd AH, Schlarbaum JP, Warshaw EM · Contact Dermatitis (2018)
Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface [PMID: 9561834 · 1998]
Becquet F, Goldschild M, Moldovan MS, Ettaiche M, Gastaud P, Baudouin C · Curr Eye Res (1998)

Long term use of topical drugs has clearly been shown to induce toxic immunopathological changes in the ocular surface. However, little is known concerning the respective roles of active compounds and preservatives. Benzalkonium chloride (BAC) is the most used preservative and its cytotoxicity is well known, but other preservatives have not yet been clearly evaluated. We thus performed a comparative study to investigate toxic side effects induced in the rat ocular surface by applications of various preservatives, with special attention to inflammatory infiltrates. A total of 35 brown Norway rats were divided into seven groups of five each. They received, for one month, in both eyes, either 0.01% cetrimonium chloride, 0.01% benzalkonium chloride, 0.01% benzododecinium bromide, 0.004% thiomersal, 0.05% methyl parahydroxybenzoate or phosphate-buffered saline (PBS), the last group remaining untreated. Then, animals were sacrificed and eyes were processed for histological and immunological procedures with monoclonal antibodies to rat immunocompetent cells. When compared to controls, all preservative-treated eyes consistently showed corneal and conjunctival damage, including epithelial alterations, various degrees of keratinization and inflammatory infiltrates at the limbus and within the conjunctival stroma and epithelium. No difference was found between the five tested drugs. This study confirms that most preservatives used in ophthalmic eyedrops may similarly induce strong histopathological and inflammatory changes in the ocular surface after short term use. Although obtained in animal model, these results confirm strong toxic side effects in patients with preexisting ocular surface disorders and/or receiving topical drugs for long periods.

The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva [PMID: 7959096 · 1994]
Mietz H, Niesen U, Krieglstein GK · Graefes Arch Clin Exp Ophthalmol (1994)

Topical medication applied chronically for the treatment of glaucoma changes the cellular profile of the conjunctiva. We wanted to determine the role of preservatives, which are usually combined with the drugs, on this effect. We applied metipranolol 0.3% and pilocarpine 2% with and without benzalkonium chloride 0.01% and cetrimonium chloride 0.004%, respectively. Twenty-four rabbits, divided into four groups, were treated for 3 months. The complete globes and the adherent bulbar conjunctiva were examined histopathologically and immunohistochemically. With special stains for collagen, a slight increase of the thickness of subepithelial collagen of the conjunctiva was present in both groups treated with medication and preservative compared with eyes treated with medication alone. This effect was also true for special antibodies for collagen type IV and alpha-smooth muscle actin in the eyes treated with pilocarpine, but not in the eyes treated with metipranolol. The results suggest that preservatives may have an additional adverse effect on the conjunctiva in addition to the effects of the medications alone.

MPF-mediated anion-π(+) interaction for high-efficiency aggregation-induced electrochemiluminescence system: application in trace cetrimonium chloride analysis [PMID: 42119435 · 2026]
Tian M, Zhang L, Wang R, Wang Y, Li W, Xu D, Chen L, Han Z · Talanta (2026)

Owing to its remarkable capability to address the core challenges of poor water-solubility and aggregation-caused quenching (ACQ) for organic luminescent probes, aggregation-induced electrochemiluminescence (AIE-ECL) has emerged as a focus of intensive research interest. Nevertheless, AIE-ECL systems still suffer from low efficiency, primarily stemming from the poor inefficient electron transfer capability, and inadequate water solubility of organic emitters. In this pioneering study, we incorporated the anion-&#x3c0; + compound MPF into the AIE-ECL system, leveraging MPF's well-documented excellent electron transfer properties. It was found that the ECL intensity of MPF is approximately 1.6-fold higher than that of its structural analogues. This significant enhancement can be attributed to its superior electrical conductivity, strong AIE activity, and unique anionic-&#x3c0; + structure. Furthermore, the MPF-based ECL system was successfully applied to the high-sensitivity detection of trace surfactant cetrimonium chloride (CC) with a low detection limit of 24.2&#x202f;nM. This work not only overcomes the long-standing challenge of low luminescence efficiency induced by insufficient electron transfer in AIE-ECL systems but also substantially expands the research and application scope of ECL technology.

よくある質問 (FAQ)

Q1. CETRIMONIUM CHLORIDE の各国公式全成分表示名称(7トラック)はどのように異なりますか?
日本化粧品工業連合会(JCIA)表示名称は 'CETRIMONIUM CHLORIDE (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'CETRIMONIUM CHLORIDE'、中国NMPA IECIC標準中国語名は '西曲氯铵' です。
Q2. CETRIMONIUM CHLORIDE のグローバル6大法域における法定配合基準 (Layer 1) は?
6大法域規制ステータス — 日本(JP): none、韓国(KR): restricted、欧州(EU): restricted、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における CETRIMONIUM CHLORIDE の通常配合濃度 (Layer 3) と適正 pH は?
主要剤形 (cleanser_rinse) において通常 1.3〜8.33%(中央値 3%)で配合され、適正pH範囲は 4〜8 です。
Q4. CETRIMONIUM CHLORIDE の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。